Skip to content Skip to footer
Subscribe Now
Viewpoints_Chris Gasink
VIEWPOINTS

Unlocking Approval: Chris Gasink from Johnson & Johnson in an Enlightening Conversation with PharmaShots

Shots:Johnson & Johnson’s (J&J) Tremfya recently received its third approval from the US FDA, supported by the pivotal QUASAR study, which demonstrated significant remission after one year of treatment in adults with moderately to severely active ulcerative colitisTremfya is a dual-binding monoclonal antibody targeting interleukin 23 (IL-23), a cytokine responsible for inflammationAt…
February 3, 2025

Read more

Viewpoints_Dale Curtis Jr
VIEWPOINTS

Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

Shots: The biopharma industry faces several challenges, including digital transformation, regulatory compliance, and managing large volumes of data Intelligent automation plays a vital role in drug discovery, clinical trials, manufacturing, and commercialization, helping optimize operations and better meet customer needs Astrix CEO Dale Curtis Jr. discusses the role of AI and machine learning in global…
January 31, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Cardiology Care and Beyond: Mina Makar from AstraZeneca in a Riveting Dialogue Exchange with PharmaShots

Shots:At ESC 2024, AstraZeneca presented insights from the real-world OverTTuRe study, exploring the challenges of early diagnosis in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) Mina Makar, SVP and Commercial Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM) Biopharmaceuticals Business Unit at AstraZeneca, shared real-world insights on how ATTR-CM manifests as cardiac symptoms Mina highlighted the…
January 27, 2025

Read more

Thoughtspot_Saurabh Chaubey
THOUGHTSPOT

Reinventing Marketing Strategies for Biopharma Companies

Shots: Conventional marketing strategies face challenges due to a lack of next-generation tools integrated into existing models. Explore the nuances of biopharma marketing, highlighting its key elements and the advantages it offers. Discover PharmaShots’ 4D model, which has been instrumental in shaping the biopharma marketing landscape. Strategically crafted marketing plans are essential for long-term sustainability,…
January 22, 2025

Read more

Exclusive_Dr. Ikshit Sharma_2025
EXCLUSIVE

Exclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots:Integrating innovation with the scientific principles of Ayurveda, AIMIL Pharmaceuticals caters to the growing needs of healthcare professionals, patients, and the animal healthcare sectorPharmaShots welcomes Dr. Ikshit Sharma, Director at AIMIL Pharmaceuticals, in a riveting conversation. Ikshit stresses the significance of making investments in research and development for creating novel therapies and addressing…
January 20, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at EADV Congress 2024: Uwe Gudat in a Stimulating Dialogue Exchange with PharmaShots

Shots: At the European Academy of Dermatology and Venereology (EADV) 2024 Congress, Biocon Biologics presented results from two pivotal P-III clinical studies. These studies supported the interchangeability between Humira and adalimumab-fkjp, as well as the biosimilarity between Bmab 1200 and Stelara for the treatment of patients with moderate-to-severe plaque psoriasis In an engaging conversation with…
January 6, 2025

Read more

New Drug Designations - November 2024
INSIGHTS+

New Drug Designations – November 2024

Shots:  PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, and NMPA  The November 2024 report covers designations granted to 28 drugs and 3 devices, encompassing 9 small molecules, 6 biologics, 7 cell and gene therapies as well as 3 medical devices Significant trends…
December 31, 2024

Read more

Viewpoints_Gerry Muhle
VIEWPOINTS

GAIN JPAC 2024: Gerry Muhle from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots: GAIN JPAC is an emerging platform where leaders in aesthetics convene to share knowledge and advance patient treatment and safety PharmaShots hosted Gerry Muhle, Head of Global Product Strategy at Galderma, who discussed the ‘Next by Galderma’ report, providing insights into the future of the aesthetics market and helping professionals better understand patient and…
December 30, 2024

Read more

Viewpoints_Jay Anders
VIEWPOINTS

Fostering Safe AI Use: Jay Anders from Medicomp in a Riveting Conversation with PharmaShots

Shots: Nearly half of FDA-approved AI medical devices lack testing on real patient data, raising significant concerns about patient safety. PharmaShots welcomes Jay Anders, CMO of Medicomp Systems, to discuss AI implementation trends in healthcare and strategies for ethical AI adoption by healthcare professionals. Jay emphasizes the importance of clinical validations to ensure the safe…
December 23, 2024

Read more

Viewpoints_Mark Genovese 
VIEWPOINTS

Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

Shots: Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024

Read more

Load more